Zacks Investment Research downgraded shares of Consort Medical (OTCMKTS:CSRMY) from a buy rating to a hold rating in a research note issued to investors on Tuesday.
According to Zacks, “Consort Medical Plc engages in the design, development, manufacture and sale of medical drug delivery devices. It operates through the Bespak and Aesica segments. Bespak segment develops and produces drug delivery devices which serves pharmaceutical companies with inhaler and auto-injector technologies. Aesica segment is a contract development and manufacturing organization which serves pharmaceutical firms with active pharmaceutical ingredient and finished dose formulation development and manufacturing services. Consort Medical Plc is headquartered in Hemel Hempstead, United Kingdom. “
Consort Medical (OTCMKTS:CSRMY) opened at $16.00 on Tuesday. Consort Medical has a 52-week low of $13.00 and a 52-week high of $16.00.
About Consort Medical
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.